LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC saw its shares rise Monday after it said the latest results from a trial of its SCIB1 ImmunoBodyÒ treatment on skin cancer had shown further evidence of tumour reduction and disease control, enhanced immune responses and "highly encouraging" survival times.
In a statement, the company said the latest result from the continuing phase 1/2 clinical trial in patients with Stage III/IV melanoma also showed that SCIB1 is safe and well-tolerated.
"As positive and consistent data continues to emerge from this study, our confidence grows that SCIB1 will play an important role in the management of melanoma. While recognizing the limitations of this open label trial, the results nonetheless detail a high rate of immune responders and a strong immune response with a drug that is well-tolerated and safe," said Lindy Durrant, joint Chief Executive of Scancell and Professor of Cancer Immunotherapy at Nottingham University.
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms. SCIB1 is its first ImmunoBody treatment.
Scancell shares were up 8.8% at 37 pence Monday morning, one of the biggest gains on AIM.
By Steve McGrath; stevemcgrath@alliancenews.com; @SteveMcGrath1
Copyright 2014 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)